|Bid||0.0850 x 0|
|Ask||0.0900 x 0|
|Day's Range||0.0850 - 0.0850|
|52 Week Range||0.0400 - 0.1700|
|Beta (5Y Monthly)||3.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO, Jan. 26, 2021 /CNW/ - A settlement hearing in the matter of Albert Hoo-Cheong Koo ("Respondent") was held by electronic hearing on January 25, 2021, before a three-member Hearing Panel of the Central Regional Council of the Mutual Fund Dealers Association of Canada ("MFDA").
* Strengthen the focus of the Company toward natural health products base assets * Cash transaction representing a non-dilutive financing of $350,000 * Sale of the non-core asset Celext07, a natural biostimulant and biopesticide with agricultural applications * Right of first refusal on potential natural health products developed by the buyer using Celext07MONTREAL, Jan. 4, 2021 /CNW/ - Lumiera Health Inc.
* A natural alternative to artificially designed sleeps aids and stress relief products. * Formulations based on the Company patented CALPXT96 ingredient.